BioXcel Therapeutics (BTAI) Uses A.I. To Discover New Drug Candidates

BioXcel Therapeutics (BTAI) is a commercial-stage biopharmaceutical company that utilizes A.I. to develop medicines in neuroscience and immuno-oncology. Last year, the FDA approved BioXcel’s agitation drug, IGALMI. It was the result of BioXcel’s big data approach in using its own A.I. engine to scan hundreds of thousands of data points to identify new therapeutic opportunities for drugs that have typically been found safe but were not shown to be effective for other indications. CEO Dr. Vimal Mehta weighs in on positive phase 2 results from BioXcel Therapeutics (BTAI) prostate cancer drug.